CA
GBT

Calton & Associates’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Calton & Associates’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,016
Closed -$409K – 291
2022
Q3 		$409K Buy
+6,016
New +$332K 0.23% 108
2022
Q2 		– Sell
-6,321
Closed -$218K – 367
2022
Q1 		$218K Sell
6,321
-4,097
-39% -$122K 0.06% 319
2021
Q4 		$304K Sell
10,418
-2,278
-18% -$70.6K 0.08% 256
2021
Q3 		$323K Buy
12,696
+6,610
+109% +$194K 0.07% 278
2021
Q2 		$219K Sell
6,086
-102
-2% -$3.98K 0.04% 367
2021
Q1 		$252K Sell
6,188
-100
-2% -$4.6K 0.05% 322
2020
Q4 		$272K Buy
6,288
+593
+10% +$29.2K 0.05% 286
2020
Q3 		$314K Buy
5,695
+265
+5% +$16.8K 0.06% 230
2020
Q2 		$343K Sell
5,430
-5
-0.1% -$343 0.07% 202
2020
Q1 		$278K Buy
5,435
+2,429
+81% +$163K 0.07% 217
2019
Q4 		$239K Buy
+3,006
New +$178K 0.05% 301

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Calton & Associates's GBT Position: Q4 2022 in Review

Calton & Associates sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 6,016 shares — an estimated $409K sold.

Calton & Associates first reported a position in GBT in Q4 2019 and held it in 11 quarters. The position peaked at $409K in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Calton & Associates reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Calton & Associates sold 6,016 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $409K.
  • Calton & Associates first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 11 quarters.
  • Calton & Associates's Global Blood Therapeutics, Inc. position peaked at $409K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Calton & Associates's 13F filing for Q4 2022, filed 18 Jan 2023.